Drugs for HER-2-positive Breast Cancer

• Corporate Author: SpringerLink (Online service)
• Other Authors: Sibilia, Maria (Editor), Zielinski, Christoph C. (Editor), Bartsch, Rupert (Editor), Grunt, Thomas W. (Editor)
• Format: Electronic eBook
• Language: English
• Published: Basel : Springer Basel, 2011.
• Series: Milestones in Drug Therapy
• Subjects: Medicine.; Cancer research.; Immunology.; Antibodies.; Pharmacology.; Internal medicine.; Oncology.; Biomedicine.; Pharmacology/Toxicology.; Cancer Research.; Internal Medicine.

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory...

Table of Contents:

• Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt)
• The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Köstler and Yosef Yarden)
• Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger)
• Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello)
• Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu)
• Pertuzumab – a HER-2 dimerisation inhibitor – for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni)
• Beyond trastuzumab: Second generation targeted therapies for HER2--positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).